Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B
Three-year path as stand-alone company culminates in takeout
Viela’s three-year journey as an independent company has culminated in a takeout.
Horizon’s $3 billion-plus buyout of Viela caps the biotech’s three-year journey as an independent company spun out from AstraZeneca’s MedImmune unit, with an IPO and a drug approval along the path to value creation.
It will be up to Horizon Therapeutics plc (NASDAQ:HZNP)